Background: Lacosamide (LCM), a novel AED (antiepileptic drug), was used as an
adjunctive treatment in patients with partial-onset seizures or without secondary …

Mood disorders such as depression and anxiety have a high prevalence in adult patients
with epilepsy, and their evaluation is crucial in choosing the most appropriate antiepileptic …

Background This retrospective, observational study used US claims data to assess retention
rates on cenobamate compared with four branded antiseizure medications (ASMs) in …

The antiepileptic drug lacosamide (LCM) is approved in the United States and the European
Union as monotherapy as well as adjunctive therapy for the treatment of focal seizures in …

Lacosamide (LCM) is a new-generation anti-seizure medication approved for monotherapy
and add-on therapy for focal-onset epilepsy. It has novel pharmacodynamics and favorable …

Purpose We describe the effectiveness of lacosamide as adjunctive therapy in patients with
epilepsy and an intellectual disability. This information is relevant, as few data exist …

We investigated the efficacy of lacosamide (LCM) polytherapy in improving seizure
outcomes and psychiatric symptoms in patients with epilepsy with psychiatric comorbidities …

Objective To evaluate the efficacy and retention rate of lacosamide (LCM) over 36 months as
a treatment for children and adolescents with focal and generalized epilepsy based on a …

Lacosamide is one of the third-generation antiseizure drugs that block voltage-gated sodium
channels by enhancing slow inactivation. The most common adverse effects of lacosamide …

Objective Lacosamide (LCM) is an antiepileptic drug (AED) with insufficient clinical
experience in patients with intellectual disability (ID). They often have more severe epilepsy …